Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 2/20 | 0.42 |
| ▸ | P2RY12 | Q9H244 | 3/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | KIT | P10721 | 7/20 | 0.39 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.39 |
| ▸ | PDE4A | P27815 | 1/20 | 0.39 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.39 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.39 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.38 |
| ▸ | DGAT1 | O75907 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4102987 | 0.93 | TP53 (0.43) | TP53MAPTKITPDE4APDE4B | |
| SCHEMBL4113600 | 0.91 | P2RY12 (0.44) | TP53P2RY12MAPTKITPDE4A | |
| SCHEMBL4101731 | 0.90 | PDGFRB (0.45) | TP53MAPTPKM | |
| SCHEMBL4122502 | 0.90 | TP53 (0.54) | TP53KIT | |
| SCHEMBL4113239 | 0.90 | PDE4A (0.45) | TP53MAPTKITPDE4APDE4B | |
| SCHEMBL4113419 | 0.89 | PDE4A (0.49) | TP53P2RY12MAPTKITEPHX2 | |
| SCHEMBL4108871 | 0.88 | KIT (0.49) | TP53P2RY12KIT | |
| SCHEMBL4118578 | 0.87 | KIT (0.53) | TP53P2RY12MAPTKITPDE4A | |
| SCHEMBL4113636 | 0.86 | KIT (0.46) | TP53P2RY12MAPTKITPDE4A | |
| SCHEMBL4114339 | 0.86 | P2RY12 (0.47) | TP53P2RY12KIT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090264415-A2 | PYRIDO(3,2-D)PYRIMIDINES AND PHARMACEUTICAL COMPOSITIONS USEFUL FOR MEDICAL TREATMENT | 4 AZA IP NV (BE) | 2009-10-22 | — | — | US | disclosed |
| US-20090036430-A1 | PYRIDO(3,2-D)PYRIMIDINES AND PHARMACEUTICAL COMPOSITIONS USEFUL FOR MEDICAL TREATMENT | 4 AZA IP NV (BE) | 2009-02-05 | — | — | US | disclosed |
| US-20080004285-A1 | PYRIDO(3,2-D)PYRIMIDINES AND PHARMACEUTICAL COMPOSITIONS USEFUL FOR MEDICAL TREATMENT | 4 AZA IP NV (BE) | 2008-01-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080004285-A1 | PYRIDO(3,2-D)PYRIMIDINES AND PHARMACEUTICAL COMPOSITIONS USEFUL FOR MEDICAL TREATMENT | PNPO, TYMP, PNP | TP53 1977/4885P2RY12 82/4885MAPT 1541/4885 |
| US-20090036430-A1 | PYRIDO(3,2-D)PYRIMIDINES AND PHARMACEUTICAL COMPOSITIONS USEFUL FOR MEDICAL TREATMENT | PNPO, TYMP, PNP | TP53 1977/4885P2RY12 82/4885MAPT 1541/4885 |
| US-20090264415-A2 | PYRIDO(3,2-D)PYRIMIDINES AND PHARMACEUTICAL COMPOSITIONS USEFUL FOR MEDICAL TREATMENT | PNPO, TYMP, PNP | TP53 1977/4885P2RY12 82/4885MAPT 1541/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.